Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Secondary Hypogonadism

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    32 result(s) found for: Secondary Hypogonadism. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2007-005640-25 Sponsor Protocol Number: Tostran2v1 Start Date*: 2008-05-08
    Sponsor Name:Greater Glasgow & Clyde Health Board
    Full Title: Effect of Tostran 2% Gel on Growth, Development & Bone Turnover in Hypogonadal Adolescent Boys
    Medical condition: Delayed puberty or hypogonadism in boys requiring pubertal induction.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10021011 Hypogonadism male LLT
    9.1 10043335 Testicular hypogonadism LLT
    9.1 10052649 Primary hypogonadism LLT
    9.1 10059594 Secondary hypogonadism LLT
    9.1 10059597 Central hypogonadism LLT
    9.1 10014692 Endocrine abnormalities of puberty HLT
    9.1 10012205 Delayed puberty LLT
    Population Age: Adolescents, Under 18 Gender: Male
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-001012-11 Sponsor Protocol Number: NAT-2017-01 Start Date*: 2017-08-01
    Sponsor Name:Acerus Biopharma Inc.
    Full Title: A multicenter, open label, variable dose, two arm pilot paediatric phase 1 PK study to evaluate testosterone nasal gel (4.5% w/w) in hypogonadal boys
    Medical condition: Primary and secondary hypogonadism
    Disease: Version SOC Term Classification Code Term Level
    20.0 10014698 - Endocrine disorders 10052649 Primary hypogonadism PT
    20.0 10014698 - Endocrine disorders 10059594 Secondary hypogonadism PT
    Population Age: Adolescents, Under 18 Gender: Male
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-004677-12 Sponsor Protocol Number: RHYTHM Start Date*: 2021-02-09
    Sponsor Name:UNIVERSITA' DEGLI STUDI DI MODENA E REGGIO EMILIA - DIPARTIMENTO DI SCIENZE BIOMEDICHE, METABOLICHE E NEUROSCIENZE
    Full Title: Pharmacodynamics and safety of human recombinant luteinising hormone in hypogonadotropic hypogonadal men.
    Medical condition: Aquired hypogonadotropic hypogonadism
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004860 10021012 Hypogonadotrophic hypogonadism LLT
    Population Age: Adults Gender: Male
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2006-002304-33 Sponsor Protocol Number: no sponsor Start Date*: 2006-09-12
    Sponsor Name:Rijnstate Hospital
    Full Title: Letrozole Treatment to Normalize Serum Testosterone in Men with Hypogonadotropic Hypogonadism due to Pituitary Damage.
    Medical condition: Hypogonadotropic hypogonadism in men with pituitary damage other than irradiation
    Disease: Version SOC Term Classification Code Term Level
    8.1 10021012 Hypogonadotrophic hypogonadism LLT
    Population Age: Adults Gender: Male
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-001258-25 Sponsor Protocol Number: MK8962-031-00 Start Date*: 2012-11-29
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A phase III, multi-center, open label, uncontrolled trial to investigate the efficacy and safety of MK-8962 (corifollitropin alfa) in combination with human Chorionic Gonadotropin (hCG) in inducing...
    Medical condition: Hypogonadotropic hypogonadism (HH) in males may result from either absent or inadequate gonadotropin-releasing hormone (GnRH) secretion by the hypothalamus or failure of pituitary gonadotropin secr...
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004860 10021012 Hypogonadotrophic hypogonadism LLT
    Population Age: Adults Gender: Male
    Trial protocol: DE (Completed) ES (Completed) IT (Completed) GB (Completed) PL (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2014-002155-25 Sponsor Protocol Number: TAK-448-2001 Start Date*: 2014-11-17
    Sponsor Name:Takeda Development Centre Europe Ltd
    Full Title: An Open-Label, Phase 2a Study to Evaluate the Pharmacodynamics of Different Dosing Regimens of TAK-448, a Kisspeptin Agonist, in Male Overweight/Obese Subjects With Hypogonadotropic Hypogonadism
    Medical condition: Hypogonadotropic Hypogonadism
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004860 10021012 Hypogonadotrophic hypogonadism LLT
    Population Age: Adults Gender: Male
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-004866-16 Sponsor Protocol Number: I5E-MC-TSAT Start Date*: 2013-06-06
    Sponsor Name:Eli Lilly and Company
    Full Title: A Randomized, Double-Blind, Placebo-Controlled Parallel Study with an Open-Label Extension to Assess the Impact of Testosterone Solution on Total Testosterone, Sex Drive and Energy in Hypogonadal Men.
    Medical condition: Male hypogonadism
    Disease: Version SOC Term Classification Code Term Level
    14.1 10014698 - Endocrine disorders 10021011 Hypogonadism male PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DE (Completed) IT (Completed) GB (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2014-004729-42 Sponsor Protocol Number: 22102014 Start Date*: 2015-04-13
    Sponsor Name:Odense University Hospital, department M [...]
    1. Odense University Hospital, department M
    2. Odense University Hospital
    Full Title: The effect of testosterone replacement in patients with hypogonadotroph hypogonadism due to opioid treatment for non-malignant disease A double-blinded, randomized and placebo-controlled trial
    Medical condition: Male Hypogonadism
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004860 10021012 Hypogonadotrophic hypogonadism LLT
    Population Age: Adults Gender: Male
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2020-002612-52 Sponsor Protocol Number: LUCAS Start Date*: 2021-02-19
    Sponsor Name:Department of Endocrinology, Rigshospitalet
    Full Title: A randomized, double-blinded, clinical, placebo-controlled trial on the effects of therapy with Letrozole and hUman Choriongonadotropin in male hypogonadism induced by illicit use of Anabolic andro...
    Medical condition: Male hypogonadism related to illicit use of anabolic androgenic steroids
    Disease: Version SOC Term Classification Code Term Level
    20.0 10014698 - Endocrine disorders 10058359 Hypogonadism PT
    21.0 10038604 - Reproductive system and breast disorders 10021926 Infertility PT
    Population Age: Adults Gender: Male
    Trial protocol: DK (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2004-004891-36 Sponsor Protocol Number: L00074TD301 Start Date*: 2005-04-01
    Sponsor Name:PIERRE FABRE MEDICAMENT
    Full Title: CROSS-OVER COMPARISON OF TESTOSTERONE SERUM LEVELS IN HYPOGONADAL MEN TREATED WITH L0074 TESTOSTERONE PATCH 60CM2 (2 patches/48H) AND ORAL TESTOSTERONE UNDECANOATE -PANTESTONE® 40mg- (2 caps, bid)
    Medical condition: Men aged > 18 years old with primary or secondary hypogonadism. Only patients meeting the inclusion criteria will be enrolled in this study.
    Disease: Version SOC Term Classification Code Term Level
    7.1 10021011 PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2010-021268-13 Sponsor Protocol Number: Letrozole2010-1 Start Date*: 2010-11-19
    Sponsor Name:University College Dublin
    Full Title: The Effects of Normalising Sex Hormone Levels in Obese Hypogonadal Men: A Prospective Randomized Comparator Controlled Parallel Arm Clinical Trial
    Medical condition: Obesity Related Male Hypogonadism
    Disease: Version SOC Term Classification Code Term Level
    12.1 10029883 Obesity LLT
    12.1 10021011 Hypogonadism male LLT
    Population Age: Adults Gender: Male
    Trial protocol: IE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-005760-42 Sponsor Protocol Number: MBGS205 Start Date*: 2016-05-25
    Sponsor Name:Mereo BioPharma 2 Limited
    Full Title: A Phase IIb multicentre, double-blind, dose-ranging, randomised, placebo-controlled study evaluating safety and efficacy of BGS649 in male obese subjects with hypogonadotropic hypogonadism
    Medical condition: Hypogonadotropic hypogonadism (HH)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004860 10021012 Hypogonadotrophic hypogonadism LLT
    Population Age: Adults Gender: Male
    Trial protocol: GB (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2020-005938-15 Sponsor Protocol Number: CloTASH-2021-2Version15.10.21 Start Date*: 2021-11-03
    Sponsor Name:Oslo University Hospital
    Full Title: Health risks and treatment of anabolic-androgenic steroid (AAS) induced hypogonadism among men – a pilot study exploring off-label use of clomiphene citrate to reduce symptoms of androgen deficienc...
    Medical condition: Anabolic androgenic steroid induced hypogonadism among men
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: NO (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-001878-18 Sponsor Protocol Number: MK8962-043 Start Date*: 2017-07-19
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase III, Multi-Center, Open Label, Single-Group Trial to Investigate the Efficacy and Safety of MK-8962 (corifollitropin alfa) in Combination with human Chorionic Gonadotropin (hCG) for Initiat...
    Medical condition: Treatment of adolescent males 14 to <18 years old with HH
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004860 10021012 Hypogonadotrophic hypogonadism LLT
    Population Age: Adolescents, Under 18 Gender: Male
    Trial protocol: IT (Completed) DK (Prematurely Ended) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2005-002607-17 Sponsor Protocol Number: TSX/01/C Start Date*: 2005-11-18
    Sponsor Name:Prostrakan Pharmaceuticals Ltd
    Full Title: Effect of Transdermal Testosterone Replacement in Hypogonadal Men with either Metabolic Syndrome or Type 2 Diabetes Mellitus
    Medical condition: Male hypogonadism is generally characterised by abnormally low serum testosterone levels. Symptoms include changes in mood, decreased bone mineral density, increased body fat, decreased muscle mass...
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (Completed) DE (Completed) BE (Completed) ES (Completed) SE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2012-000870-51 Sponsor Protocol Number: CMCS240281 Start Date*: 2013-02-25
    Sponsor Name:Unidad de Gestión Clínica de Endocrinología y Nutrición
    Full Title: RANDOMIZED CLINICAL TRIAL TO ASSESS THE EFFICACY OF TESTOSTERONE UNDECANOATE, METFORMIN, OR THE COMBINATION OF BOTH, FOR THE TREATMENT OF ISOLATED HYPOGONADOTROPIC HYPOGONADISM AND ERECTILE DYSFUNC...
    Medical condition: Isolated hypogonadotropic hypogonadism related to obesity
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-000469-39 Sponsor Protocol Number: B9R-HL-GDGN Start Date*: 2007-05-02
    Sponsor Name:Oy Eli Lilly Finland Ab
    Full Title: An Open Label Follow-up Study of Patients Who Participated in Clinical Study B9R-HL-GDDV. A Phase IV, one-arm follow-up study to assess final adult results of GH treatment in patients with the Pra...
    Medical condition: Prader-Willi syndrome
    Disease: Version SOC Term Classification Code Term Level
    9.1 10036476 Prader-Willi syndrome LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: View results
    EudraCT Number: 2007-006305-25 Sponsor Protocol Number: 2007-006305-25 Start Date*: 2008-02-15
    Sponsor Name:Karolinska University Hospital
    Full Title: Effects of rimonabant (Acomplia) on obesity in adults with Prader-Willi Syndrome
    Medical condition: Obese adults with Prader Willi Syndrome
    Disease: Version SOC Term Classification Code Term Level
    9.1 10036476 Prader-Willi syndrome LLT
    9.1 10029883 Obesity LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-000660-33 Sponsor Protocol Number: ZAF-312 Start Date*: 2015-09-30
    Sponsor Name:Zafgen Inc.
    Full Title: Randomized, Double-Blind, Placebo Controlled, Phase 3 Trial of Beloranib in Obese Subjects with Prader-Willi Syndrome to Evaluate Food-related Behavior, Total Body Weight, and Safety Over 52 Weeks
    Medical condition: Improvement of Hyperphagia and related behaviors as well as Body Composition/Overweight in Prader-Willi-Syndrome
    Disease: Version SOC Term Classification Code Term Level
    18.0 10010331 - Congenital, familial and genetic disorders 10036476 Prader-Willi syndrome PT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: SE (Prematurely Ended) ES (Prematurely Ended) BE (Prematurely Ended) FR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-000931-16 Sponsor Protocol Number: 1054 Start Date*: 2008-08-05
    Sponsor Name:Dr G I Hackett
    Full Title: 1054 -FINAL VERSION 30th Dec 2007 Clinical and biochemical improvement in Type 2 diabetic parameters in type 2 diabetic men with symptomatic testosterone deficiency syndrome (TDS). A double blind...
    Medical condition: Male Type 2 diabetics with symptomatic testosterone deficiency and confirmed low levels of serum testosterone
    Disease:
    Population Age: Gender:
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 05 08:48:51 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA